Page last updated: 2024-12-08

sparsomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Sparsomycin: An antitumor antibiotic produced by Streptomyces sparsogenes. It inhibits protein synthesis in 70S and 80S ribosomal systems. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID129631779
MeSH IDM0020197

Synonyms (1)

Synonym
sparsomycin

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Possible long-range retinotoxic effects of EdSm were investigated in tumour-bearing mice, cured after surviving treatment with LD50 doses of EdSm, by assaying the protein biosynthetic capacity of the retinal by assaying the ocular rhodopsin and opsin levels as parameters."( Antitumour activity and retinotoxicity of ethyldeshydroxy-sparsomycin in mice.
Bovee, PH; De Grip, WJ; De Vos, D; Hofs, HP; Ottenheijm, HC; Wagener, DJ; Winkens, HJ, 1995
)
0.29

Pharmacokinetics

ExcerptReferenceRelevance
" This compound was selected for preclinical pharmacokinetic studies because of its high in vitro and in vivo antitumor activity."( Pharmacokinetics of the antitumor antibiotic n-pentyl-sparsomycin in beagle dogs.
Garzotto, M; Ottenheijm, HC; van den Broek, LA; van der Kleijn, E; Vree, TB; Wagener, DJ; Zylicz, Z, 1990
)
0.28
" Pharmacokinetic evaluation in beagle dogs was performed using either single iv bolus or continuous infusion administrations."( Preclinical pharmacokinetics of the antitumor antibiotic deshydroxy-sparsomycin in beagle dogs.
Garzotto, M; Ottenheijm, HC; van den Broek, LA; van der Kleijn, E; Vree, TB; Wagener, DJ; Zylicz, Z,
)
0.13

Compound-Compound Interactions

ExcerptReferenceRelevance
"The efficacy of cisplatin (CDDP) in combination with the protein synthesis inhibitor ethyldeshydroxysparsomycin (EDSM) has been tested in two tumor models at various schedules."( Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatin.
De Grip, WJ; De Valk-Bakker, V; De Vos, D; Doesburg, WH; Hofs, HP; Ottenheijm, HC; Van Rennes, H; Wagener, DJ, 1995
)
0.29
" Our results show that in the B16 tumor model EDSM is not able to potentiate any of these drugs, whereas antagonism is seen in combination with doxo-rubicin (DX)."( Schedule-dependent enhancement of antitumor activity of ethyldeshydroxy-sparsomycin in combination with classical antineoplastic agents.
de Grip, WJ; de Valk-Bakker, V; de Vos, D; Doesburg, WH; Hofs, HP; Ottenheijm, HC; van Rennes, H; Wagener, DJ, 1995
)
0.29
" When drug ratios were used, synergism was observed upon pre- and post-treatment in combination with cisplatin, cytosine arabinoside (Ara-C), methotrexate (MTX) and 5-fluorouracil (5-FU)."( Concentration and sequence dependent synergism of ethyldeshydroxy-sparsomycin in combination with antitumor agents.
de Grip, WJ; de Valk-Bakker, V; Hofs, HP; Ottenheijm, HC; van Rennes, H; Wagener, DJ, 1994
)
0.29

Bioavailability

ExcerptReferenceRelevance
"We have developed a first generation of hybrid sparsomycin-linezolid compounds into a new family of orally bioavailable biaryloxazolidinones that have activity against both linezolid-susceptible and -resistant gram-positive bacteria as well as the fastidious gram-negative bacteria Haemophilus influenzae and Moraxella catarrahalis."( Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics.
Bhattacharjee, A; Chen, S; Chen, Y; Duffy, E; Farmer, J; Goldberg, J; Hanselmann, R; Ippolito, JA; Johnson, G; Lou, R; Orbin, A; Oyelere, A; Salvino, J; Springer, D; Tran, J; Wang, D; Wu, Y; Zhou, J, 2008
)
0.35

Dosage Studied

ExcerptRelevanceReference
" EdSm showed a clear dose-response effect in vitro."( Antitumour activity and retinotoxicity of ethyldeshydroxy-sparsomycin in mice.
Bovee, PH; De Grip, WJ; De Vos, D; Hofs, HP; Ottenheijm, HC; Wagener, DJ; Winkens, HJ, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (120)

TimeframeStudies, This Drug (%)All Drugs %
pre-199068 (56.67)18.7374
1990's26 (21.67)18.2507
2000's21 (17.50)29.6817
2010's5 (4.17)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (2.38%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other123 (97.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]